pembrolizumab,enfortumab vedotin,durvalumab,nivolumab,tremelimumab,gemcitabine,avelumab,ipilimumab
astellas,merck,astrazeneca,bms,pfizer,seagen,roche,takeda
['avelumab', 'mibc', 'pembro', 'cisplatin', 'durva', 'key,note,866', 'check,mate,274', 'niagara', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'volga', 'imvigor010', 'nivo', 'bladder', 'swog gap']
optimizing survival for patients with muscle-invasive #bladdercancer. presented by . #gu23 written coverage by &gt; 
Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology